Clinical Trial Update: Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study [Phase 2, Phase 3]

View source ↗

Summary

A prospective single-arm multicenter Phase 2/3 trial evaluating the combination of sorafenib and venetoclax as pre-emptive therapy for measurable residual disea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Nexavar (Sorafenib)
• Venclyxto (Venetoclax)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING